the Center for Medicare and Medicaid Innovation (CMMI) released a request for applications (RFA) for the Cell and Gene Therapy Access Model. Eligible manufacturers include those that have a gene therapy approved or licensed by the Food and Drug Administration (FDA) for sickle cell disease and participate in the Medicaid Drug Rebate Program (MDRP). Responses are due by May 1… (Slifer, March 7, 2024) #Demonstration Programs, #Drug Pricing